Equities research analysts expect Danaher Co. (NYSE:DHR) to report $1.09 earnings per share for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Danaher’s earnings, with the highest EPS estimate coming in at $1.11 and the lowest estimate coming in at $1.07. Danaher reported earnings per share of $0.99 during the same quarter last year, which would indicate a positive year over year growth rate of 10.1%. The company is expected to issue its next earnings report on Thursday, July 19th.
On average, analysts expect that Danaher will report full year earnings of $4.45 per share for the current year, with EPS estimates ranging from $4.40 to $4.55. For the next financial year, analysts expect that the business will post earnings of $4.82 per share, with EPS estimates ranging from $4.75 to $4.94. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Danaher.
Danaher (NYSE:DHR) last posted its quarterly earnings results on Thursday, April 19th. The conglomerate reported $0.99 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.05. Danaher had a net margin of 13.56% and a return on equity of 11.39%. The company had revenue of $4.70 billion during the quarter, compared to the consensus estimate of $4.54 billion. During the same period last year, the firm earned $0.85 EPS. The company’s revenue for the quarter was up 11.6% on a year-over-year basis.
DHR has been the subject of a number of research reports. Barclays initiated coverage on shares of Danaher in a research report on Thursday, February 15th. They set an “overweight” rating and a $110.00 price target for the company. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $113.00 price objective for the company in a research report on Thursday. Royal Bank of Canada restated a “hold” rating and set a $98.00 price objective on shares of Danaher in a research report on Wednesday, January 31st. Stifel Nicolaus lifted their price objective on Danaher from $110.00 to $115.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Finally, ValuEngine upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $105.56.
In other Danaher news, CFO Daniel L. Comas sold 78,379 shares of the business’s stock in a transaction on Monday, April 23rd. The stock was sold at an average price of $101.67, for a total value of $7,968,792.93. Following the completion of the transaction, the chief financial officer now directly owns 148,769 shares in the company, valued at approximately $15,125,344.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rainer Blair sold 51,080 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $97.26, for a total value of $4,968,040.80. Following the completion of the transaction, the insider now owns 50,477 shares of the company’s stock, valued at $4,909,393.02. The disclosure for this sale can be found here. Insiders sold a total of 318,157 shares of company stock valued at $31,990,824 over the last quarter. 11.90% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. CIBC World Markets Inc. raised its holdings in Danaher by 12.5% in the 1st quarter. CIBC World Markets Inc. now owns 22,562 shares of the conglomerate’s stock valued at $2,209,000 after acquiring an additional 2,510 shares during the last quarter. Xact Kapitalforvaltning AB grew its stake in shares of Danaher by 5.6% during the 1st quarter. Xact Kapitalforvaltning AB now owns 116,596 shares of the conglomerate’s stock valued at $11,416,000 after buying an additional 6,219 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp grew its stake in shares of Danaher by 113.9% during the 1st quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 80,200 shares of the conglomerate’s stock valued at $7,852,000 after buying an additional 42,700 shares during the period. Griffin Asset Management Inc. grew its stake in shares of Danaher by 2.8% during the 1st quarter. Griffin Asset Management Inc. now owns 72,962 shares of the conglomerate’s stock valued at $7,144,000 after buying an additional 1,980 shares during the period. Finally, Private Capital Group LLC grew its stake in shares of Danaher by 445.0% during the 1st quarter. Private Capital Group LLC now owns 1,744 shares of the conglomerate’s stock valued at $171,000 after buying an additional 1,424 shares during the period. Institutional investors own 76.69% of the company’s stock.
DHR stock opened at $101.25 on Thursday. Danaher has a 12-month low of $78.97 and a 12-month high of $104.82. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.59 and a quick ratio of 1.15. The company has a market cap of $70.73 billion, a PE ratio of 24.28, a P/E/G ratio of 1.90 and a beta of 1.03.
The firm also recently declared a quarterly dividend, which will be paid on Friday, July 27th. Shareholders of record on Friday, June 29th will be issued a $0.16 dividend. The ex-dividend date of this dividend is Thursday, June 28th. This represents a $0.64 annualized dividend and a yield of 0.63%. Danaher’s dividend payout ratio (DPR) is presently 15.88%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Get a free copy of the Zacks research report on Danaher (DHR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.